CoChat

Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction

Open access
Smith, Ruben, Petersén, Åsa, Bates, Gillian P., Brundin, Patrik, Li, Jia-Yi · 2005 · Neurobiology of Disease
Cited by 38

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Huntington's disease (HD) is a hereditary neurodegenerative disorder characterized by progressive psychiatric, cognitive, and motor disturbances. We studied the expression of synaptic vesicle proteins in the R6/1 transgenic mouse model of HD. We observed that the levels of rabphilin 3A, a protein involved in exocytosis, is substantially decreased in synapses of most brain regions in R6/1 mice. The appearance of the reduction coincides with the onset of motor deficits and behavioral disturbances. Double immunohistochemistry did not show colocalization between rabphilin 3A and huntingtin aggregates in the HD mice. Using in situ hybridization, we demonstrated that rabphilin 3A mRNA expression was substantially reduced in the R6/1 mouse cortex compared to wild-type mice. Our results indicate that a decrease in mRNA levels underlie the depletion of protein levels of rabphilin 3A, and we suggest that this reduction may be involved in causing impaired synaptic transmission in R6/1 mice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2005.05.008

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 59

  1. Arribas, 1997, The stimulatory effect of rabphilin 3a on regulated exocytosis from insulin-secreting cells does not require an association-dissociation cycle with membranes mediated by rab 3, Eur. J. Cell Biol., 74, 209
  2. Behrens, 2002, Impaired glutamate transport and glutamate–glutamine cycling: downstream effects of the huntington mutation, Brain, 125, 1908, 10.1093/brain/awf180 · DOI · Paper page
  3. Burns, 1998, Rabphilin-3a: a multifunctional regulator of synaptic vesicle traffic, J. Gen. Physiol., 111, 243, 10.1085/jgp.111.2.243 · DOI · Paper page
  4. Caramins, 2003, Genetically confirmed clinical Huntington's disease with no observable cell loss, J. Neurol. Neurosurg. Psychiatry, 74, 968, 10.1136/jnnp.74.7.968 · DOI
  5. Cenci, 1998, l-dopa-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA, Eur. J. Neurosci., 10, 2694, 10.1046/j.1460-9568.1998.00285.x · DOI · Paper page
  6. Cepeda, 2003, Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease, J. Neurosci., 23, 961, 10.1523/JNEUROSCI.23-03-00961.2003 · DOI · Paper page
  7. Chung, 1995, Evidence that the rab3a-binding protein, rabphilin3a, enhances regulated secretion. Studies in adrenal chromaffin cells, J. Biol. Chem., 270, 16714, 10.1074/jbc.270.28.16714 · DOI · Paper page
  8. Chung, 1999, Comparison of the effects on secretion in chromaffin and pc12 cells of rab3 family members and mutants. Evidence that inhibitory effects are independent of direct interaction with rabphilin3, J. Biol. Chem., 274, 18113, 10.1074/jbc.274.25.18113 · DOI
  9. Dunah, 2002, Sp1 and tafii130 transcriptional activity disrupted in early Huntington's disease, Science, 2, 2
  10. Edwardson, 2003, Expression of mutant huntingtin blocks exocytosis in pc12 cells by depletion of complexin II, J. Biol. Chem., 278, 30849, 10.1074/jbc.M304615200 · DOI · Paper page
  11. Engqvist-Goldstein, 1999, An actin-binding protein of the sla2/huntingtin interacting protein 1 family is a novel component of clathrin-coated pits and vesicles, J. Cell Biol., 147, 1503, 10.1083/jcb.147.7.1503 · DOI · Paper page
  12. Fykse, 1995, Phosphorylation of rabphilin-3a by Ca2+/calmodulin- and cAMP-dependent proteins kinases in vitro, J. Neurosci., 15, 2385, 10.1523/JNEUROSCI.15-03-02385.1995 · DOI · Paper page
  13. Geppert, 1994, The role of rab3a in neurotransmitter release, Nature (London), 369, 493, 10.1038/369493a0 · DOI · Paper page
  14. Greengard, 1993, Synaptic vesicle phosphoproteins and regulation of synaptic function, Science, 259, 780, 10.1126/science.8430330 · DOI · Paper page
  15. Group, 1993, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes, Cell, 72, 971, 10.1016/0092-8674(93)90585-E · DOI · Paper page
  16. Gundersen, 1988, Some new, simple and efficient stereological methods and their use in pathological research and diagnosis, APMIS, 96, 379, 10.1111/j.1699-0463.1988.tb05320.x · DOI · Paper page
  17. Inagaki, 1994, Cloning of a mouse rabphilin-3a expressed in hormone-secreting cells, J. Biochem. (Tokyo), 116, 239, 10.1093/oxfordjournals.jbchem.a124512 · doi:10.1093/oxfordjournals.jbchem.a124512
  18. Jahn, 1999, Membrane fusion and exocytosis, Annu. Rev. Biochem., 68, 863, 10.1146/annurev.biochem.68.1.863 · DOI · Paper page
  19. Kalchman, 1997, Hip1, a human homologue of S. cerevisiae sla2p, interacts with membrane-associated huntingtin in the brain, Nat. Genet., 16, 44, 10.1038/ng0597-44 · DOI · Paper page
  20. Kegel, 2002, Huntingtin is present in the nucleus, interacts with the transcriptional corepressor c-terminal binding protein, and represses transcription, J. Biol. Chem., 277, 7466, 10.1074/jbc.M103946200 · DOI · Paper page
  21. Klapstein, 2001, Electrophysiological and morphological changes in striatal spiny neurons in r6/2 Huntington's disease transgenic mice, J. Neurophysiol., 86, 2667, 10.1152/jn.2001.86.6.2667 · DOI · Paper page
  22. Komuro, 1996, Involvement of rabphilin-3a in Ca2+-dependent exocytosis from pc12 cells, Biochem. Biophys. Res. Commun., 219, 435, 10.1006/bbrc.1996.0251 · DOI
  23. Leegwater-Kim, 2004, The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration, NeuroRx, 1, 128, 10.1602/neurorx.1.1.128 · DOI
  24. Legendre-Guillemin, 2002, Hip1 and hip12 display differential binding to f-actin, ap2, and clathrin. Identification of a novel interaction with clathrin light chain, J. Biol. Chem., 277, 19897, 10.1074/jbc.M112310200 · DOI · Paper page
  25. Li, 1996, Rabphilin-3a is transported with fast anterograde axonal transport and associated with synaptic vesicles, Synapse, 23, 79, 10.1002/(SICI)1098-2396(199606)23:2<79::AID-SYN3>3.0.CO;2-D · DOI
  26. Li, 1994, Synaptic targeting of rabphilin-3a, a synaptic vesicle Ca2+/phospholipid-binding protein, depends on rab3a/3c, Neuron, 13, 885, 10.1016/0896-6273(94)90254-2 · DOI · Paper page
  27. Li, 1995, A huntingtin-associated protein enriched in brain with implications for pathology, Nature, 378, 398, 10.1038/378398a0 · DOI · Paper page
  28. Li, 2002, Interaction of huntington disease protein with transcriptional activator sp1, Mol. Cell. Biol., 22, 1277, 10.1128/MCB.22.5.1277-1287.2002 · DOI · Paper page
  29. Li, 2003, Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release, Hum. Mol. Genet., 12, 2021, 10.1093/hmg/ddg218 · DOI · Paper page
  30. Li, 2003, Huntington's disease: a synaptopathy?, Trends Mol. Med., 9, 414, 10.1016/j.molmed.2003.08.006 · DOI · Paper page
  31. Lievens, 2002, Abnormal phosphorylation of synapsin i predicts a neuronal transmission impairment in the r6/2 Huntington's disease transgenic mice, Mol. Cell. Neurosci., 20, 638, 10.1006/mcne.2002.1152 · DOI
  32. Mangiarini, 1996, Exon 1 of the hd gene with an expanded cag repeat is sufficient to cause a progressive neurological phenotype in transgenic mice, Cell, 87, 493, 10.1016/S0092-8674(00)81369-0 · DOI · Paper page
  33. Miller, 2003, Cysteine string protein (csp) inhibition of n-type calcium channels is blocked by mutant huntingtin, J. Biol. Chem., 278, 53072, 10.1074/jbc.M306230200 · DOI · Paper page
  34. Mizuno, 2000, An autopsy case with clinically and molecular genetically diagnosed Huntington's disease with only minimal non-specific neuropathological findings, Clin. Neuropathol., 19, 94
  35. Modregger, 2002, Pacsin 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains, Hum. Mol. Genet., 11, 2547, 10.1093/hmg/11.21.2547 · DOI · Paper page
  36. Morton, 2001, Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease, J. Neurochem., 76, 166, 10.1046/j.1471-4159.2001.00059.x · DOI · Paper page
  37. Morton, 2001, Abnormalities in the synaptic vesicle fusion machinery in Huntington's disease, Brain Res. Bull., 56, 111, 10.1016/S0361-9230(01)00611-6 · DOI
  38. Murphy, 2000, Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation, J. Neurosci., 20, 5115, 10.1523/JNEUROSCI.20-13-05115.2000 · DOI · Paper page
  39. Nicniocaill, 2001, Altered striatal amino acid neurotransmitter release monitored using microdialysis in r6/1 huntington transgenic mice, Eur. J. Neurosci., 13, 206, 10.1046/j.0953-816X.2000.01379.x · DOI · Paper page
  40. Nucifora, 2001, Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity, Science, 291, 2423, 10.1126/science.1056784 · DOI · Paper page
  41. Ohya, 1998, Involvement of rabphilin3 in endocytosis through interaction with rabaptin5, J. Biol. Chem., 273, 613, 10.1074/jbc.273.1.613 · DOI · Paper page
  42. Petersen, 2002, Evidence for dysfunction of the nigrostriatal pathway in the r6/1 line of transgenic Huntington's disease mice, Neurobiol. Dis., 11, 134, 10.1006/nbdi.2002.0534 · DOI
  43. Petersen, 2005, Orexin loss in Huntington's disease, Hum. Mol. Genet., 14, 39, 10.1093/hmg/ddi004 · DOI · Paper page
  44. Qin, 2004, Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction, J. Neurosci., 24, 269, 10.1523/JNEUROSCI.1409-03.2004 · DOI · Paper page
  45. Schluter, 1999, Rabphilin knock-out mice reveal that rabphilin is not required for rab3 function in regulating neurotransmitter release, J. Neurosci., 19, 5834, 10.1523/JNEUROSCI.19-14-05834.1999 · DOI · Paper page
  46. Shirataki, 1993, Rabphilin-3a, a putative target protein for smg p25a/rab3a p25 small gtp-binding protein related to synaptotagmin, Mol. Cell. Biol., 13, 2061, 10.1128/MCB.13.4.2061 · DOI · Paper page
  47. Shirataki, 1994, Rabphilin-3a is associated with synaptic vesicles through a vesicle protein in a manner independent of rab3a, J. Biol. Chem., 269, 32717, 10.1016/S0021-9258(20)30049-1 · DOI · Paper page
  48. Singaraja, 2002, Hip14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis, Hum. Mol. Genet., 11, 2815, 10.1093/hmg/11.23.2815 · DOI · Paper page
  49. Steffan, 2000, The Huntington's disease protein interacts with p53 and creb-binding protein and represses transcription, Proc. Natl. Acad. Sci. U. S. A., 97, 6763, 10.1073/pnas.100110097 · DOI · Paper page
  50. Strausberg, 2002, Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences, Proc. Natl. Acad. Sci. U. S. A., 99, 16899, 10.1073/pnas.242603899 · DOI · Paper page
  51. Sugars, 2003, Transcriptional abnormalities in huntington disease, Trends Genet., 19, 233, 10.1016/S0168-9525(03)00074-X · DOI · Paper page
  52. Towbin, 1979, Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications, Proc. Natl. Acad. Sci. U. S. A., 76, 4350, 10.1073/pnas.76.9.4350 · DOI · Paper page
  53. Usdin, 1999, Impaired synaptic plasticity in mice carrying the Huntington's disease mutation, Hum. Mol. Genet., 8, 839, 10.1093/hmg/8.5.839 · DOI · Paper page
  54. Vonsattel, 1998, Huntington disease, J. Neuropathol. Exp. Neurol., 57, 369, 10.1097/00005072-199805000-00001 · DOI · Paper page
  55. Vonsattel, 1985, Neuropathological classification of Huntington's disease, J. Neuropathol. Exp. Neurol., 44, 559, 10.1097/00005072-198511000-00003 · DOI · Paper page
  56. Wanker, 1997, Hip-i: a huntingtin interacting protein isolated by the yeast two-hybrid system, Hum. Mol. Genet., 6, 487, 10.1093/hmg/6.3.487 · DOI · Paper page
  57. Wyttenbach, 2001, Polyglutamine expansions cause decreased cre-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease, Hum. Mol. Genet., 10, 1829, 10.1093/hmg/10.17.1829 · DOI · Paper page
  58. Yamaguchi, 1993, Two functionally different domains of rabphilin-3a, rab3a p25/smg p25a-binding and phospholipid- and Ca2+-binding domains, J. Biol. Chem., 36, 27164, 10.1016/S0021-9258(19)74232-X · DOI · Paper page
  59. Zuccato, 2001, Loss of huntingtin-mediated bdnf gene transcription in Huntington's disease, Science, 293, 493, 10.1126/science.1059581 · DOI · Paper page

Cited by

See all 38

Metadata

Authors
Smith, R., Petersén, Å., Bates, G. P., Brundin, P., & Li, J.-Y.
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2005-12
Volume
20
Issue
3
Pages
673-684
ISSN
0969-9961 (ISSN-L)
OpenAlex
W1984667853
Cited by
38
References
4
FWCI
1.47
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.